Royal Bank Of Canada Tcr2 Therapeutics Inc. Transaction History

Royal Bank Of Canada

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$1.86 - $3.75 $107 - $217	-58 Reduced 40.56%	85 $0
Q2 2022 Aug 15, 2022	SELL	$2.11 - $2.94 $3,831 - $5,339	-1,816 Reduced 92.7%	143 $0
Q1 2022 May 16, 2022	SELL	$2.4 - $4.71 $11,198 - $21,976	-4,666 Reduced 70.43%	1,959 $5,000
Q4 2021 Feb 14, 2022	BUY	$4.58 - $8.34 $16,135 - $29,381	3,523 Added 113.57%	6,625 $31,000
Q3 2021 Nov 15, 2021	BUY	$8.44 - $18.35 $7,165 - $15,579	849 Added 37.68%	3,102 $27,000
Q2 2021 Aug 16, 2021	BUY	$16.41 - $24.71 $36,971 - $55,671	2,253 New	2,253 $36,000

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.